Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine the safety and benefit of Thalidomide with primary sclerosing cholangitis (PSC). This is a six month study.

Clinical Trial Description

At entry, patients will have a complete history and physical, blood tests, ultrasound, and will complete questionnaires. Eligible patients will take Thalidomide 400 mg once a day in the evening. Patients will start a dose of 100 mg per day for two weeks, increasing by 100 mg per day every two weeks to a maximum dose of 400 mg per day for 6 months. Patients will return at 6 months for an evaluation, blood tests and completion of questionnaires. Blood tests will be performed by mailed-in kits at 3 months. Patients will receive weekly phone calls for the first 2 months and bi-monthly thereafter. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00953615
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Terminated
Phase	Phase 2
Start date	April 2006
Completion date	May 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02239211` - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis	Phase 2
Withdrawn	`NCT03216876` - A Study Of Ursolic Acid For Primary Sclerosing Cholangitis	Phase 1
Recruiting	`NCT02605213` - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Phase 4
Recruiting	`NCT01688024` - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis	Phase 2
Completed	`NCT03041662` - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Completed	`NCT05866809` - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis	Phase 2
Recruiting	`NCT05618145` - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting	`NCT02446665` - Disease Status in Primary Sclerosing Cholangitis by Elastography	N/A
Completed	`NCT02247934` - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)	N/A
Completed	`NCT01088607` - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis	Phase 1
Terminated	`NCT01142323` - Pilot Study of Fenofibrate for PSC	Phase 1/Phase 2
Terminated	`NCT04060147` - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis	Phase 1
Recruiting	`NCT04133792` - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)	Phase 3
Active, not recruiting	`NCT04595825` - CM-101 in PSC Patients -The SPRING Study	Phase 2
Recruiting	`NCT03183570` - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT	Early Phase 1
Completed	`NCT02943460` - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis	Phase 2
Completed	`NCT00951327` - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)	N/A
Completed	`NCT04024813` - A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC	Phase 2
Recruiting	`NCT05912387` - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study	Early Phase 1
Completed	`NCT02884557` - NKT Role in the Regulation of the Inflammatory Bowel Disease	N/A